GlassScriptPhysician profile
Elie S Aoun
NPI 1184885634
$322,979.19
in general payments reported to CMS, 2019-2025
18 companies · $81K in 2025
The $81K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $6,987 · 2021: $28K · 2022: $14K · 2023: $68K · 2024: $86K · 2025: $81K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $182K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $24K · Travel and Lodging: $19K · Food and Beverage: $5,829 · Consulting Fee: $2,275 · Education: $1,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $182,105.16 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $24,437.50 |
| Travel and Lodging | $18,750.00 |
| Food and Beverage | $5,829.29 |
| Consulting Fee | $2,275.00 |
| Education | $1,160.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102,243.60 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Phathom Pharmaceuticals, INC. | $71,810.79 | 2024-2025 | Voquezna |
| Genzyme Corporation | $57,100.98 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $27,696.25 | 2022-2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $26,341.21 | 2023-2025 | Dupixent |
| Redhill Biopharma INC. | $12,230.87 | 2020-2022 | |
| Abbvie INC. | $11,999.37 | 2020-2024 | Skyrizi, Rinvoq |
| Alnylam Pharmaceuticals INC. | $6,535.00 | 2020-2021 | |
| Allergan, INC. | $4,198.35 | 2019 | |
| Bausch Health US, LLC | $2,335.28 | 2025 | |
| Ironwood Pharmaceuticals, INC | $226.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $91.87 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.52 | 2024-2025 | Entyvio |
| Ethicon US, LLC | $37.50 | 2019 | |
| Ardelyx, INC. | $28.74 | 2023 | Ibsrela |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $20.75 | 2022 | |
| Janssen Biotech, INC. | $18.88 | 2024 | Stelara |
| Pfizer INC. | $15.64 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elie Aoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.